Glumetinib

Phase 3Small molecule

Glumetinib is one of 87 small molecule programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastroesophageal Junction AdenocarcinomaRecruiting

Non-Small Cell Lung CancerRecruiting

Gastroesophageal Junction AdenocarcinomaPhase 2

Recruiting

Non-Small Cell Lung CancerPhase 3

Recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Navelbine

PPierre Fabre Medicament

Phase 3

24 2

Pyrotinib

HHengrui Therapeutics, Inc.

Phase 3

3 3

Glumetinib

HHaihe Biopharma Co., Ltd.

Phase 3

5 4

Remeron

OOrganon and Co

Preclinical

1 5

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—6

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 9

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 10

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Gastroesophageal Junction Adenocarcinoma

NCT06947291

Q2 2028

Phase 2Not yet recruiting

Non-Small Cell Lung Cancer

NCT06525350

Q1 2029

Phase 3Recruiting

Non-Small Cell Lung Cancer

NCT06829459

Q1 2030

PreclinicalNot yet recruiting

Non-Small Cell Lung Cancer

NCT06908772

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer5 trials

A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs

Recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT06829459·350 enrolled

A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer

Not yet recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT06525350·256 enrolled

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Recruiting·HHaihe Biopharma Co., Ltd.·Phase 1/2·NCT04270591·183 enrolled

Show 2 more trials

Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors

Unknown status·HHaihe Biopharma Co., Ltd.·Phase 1/2·NCT04338243·70 enrolled

A Multicenter Phase II/III Clinical Study on the Efficacy and Safety of Glumetinib Combined With Osimertinib as First-Line Treatment in Non-Small Cell Lung Cancer Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression

Not yet recruiting·SShanghai JMT-Bio Inc.·Preclinical·NCT06908772·390 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

Recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT06947291·350 enrolled

Single Dose1 trial

Single Dose Glumetinib in Healthy Chinese Male Subjects

Completed·HHaihe Biopharma Co., Ltd.·Phase 1·NCT05507294·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Glumetinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Glumetinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Glumetinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Haihe Biopharma Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHaihe Biopharma Co., Ltd.

Glumetinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Q1 2029

Q1 2030

Trials by Indication[1]

Non-Small Cell Lung Cancer5 trials

Gastroesophageal Junction Adenocarcinoma1 trial

Single Dose1 trial

References

Drug Info

Quick Facts

Related News